A Dutch-American biotech is out with $65 million in Series A funding to get into the clinic with what it calls an expanded scope of the popular antibody-drug conjugates class after a decade of legwork iterating on the original click chemistry findings that led to last year’s Nobel Prize.

Read the article on Biopharmadive

By BioWorld Twelve years on from spinning out of Philips Healthcare, Tagworks Pharmaceuticals BV has raised $65 million in a series A round to take a new generation of antibody-drug conjugates (ADCs) based on click chemistry into the clinic. Read more.

By BioCentury Netherlands-based Tagworks is using click chemistry to simultaneously accomplish on-target activation of ADCs and off-target deactivation of radiopharmaceuticals. After spinning out of Philips Healthcare in 2011, the company has announced a $65 million series A round co-led by Ysios Capital and Gilde Healthcare. Download the complete article here.

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target deactivation of radiopharmaceuticals Proceeds will be used to advance the lead program, a …

Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless receive prize for their work on reactions that quickly link molecules and the application of the reactions in living cells Three scientists have won the 2022 Nobel Prize in Chemistry: Carolyn R. Bertozzi of Stanford University, Morten Meldal of the University …

Bioorthogonal chemistry, already a workhorse of drug discovery research, prepares for the leap into human testing. Researchers at the Memorial Sloan Kettering Cancer Center in New York are preparing the first test in humans of a new type of diagnostic that combines a radioisotope and antibody via bioorthogonal ‘click’ chemistry. …